[HTML][HTML] 免疫检查点抑制剂在小细胞肺癌治疗中的应用与临床试验进展

张惠秋, 李西阳, 李西川, 苏延军 - Chinese Journal of Lung …, 2021 - ncbi.nlm.nih.gov
小细胞肺癌( small cell lung cancer, SCLC) 是一种神经内分泌型肿瘤, 病情进展快、
恶性程度高、 易复发、 预后极差。 在过去的30 余年中, SCLC 的临床治疗策略以化疗和放疗为 …

[HTML][HTML] 21 色流式检测人非小细胞肺癌组织中免疫细胞亚群方案的建立

GUO Tingting, XIE Hongguan - Chinese Journal of Lung Cancer, 2024 - ncbi.nlm.nih.gov
背景与目的肺癌组织的免疫微环境已成为关注的重点, 随着多色流式的兴起,
流式检测肺癌免疫微环境成为重要的手段, 但多为检测细胞亚群占比或主要细胞亚群功能 …

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer.

H Zhang, LI Xiyang, LI Xichuan… - Chinese Journal of …, 2021 - search.ebscohost.com
Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high
malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the …

Effect of UBR5 on the tumor microenvironment and its related mechanisms in cancer

G Wang, S Yin, J Afrifa, G Rong, S Jiang… - Oncology and …, 2021 - journals.lww.com
Objective UBR5, recently identified as a potential target for cancer therapeutics, is
overexpressed in multiple malignant tumors. In addition, it is closely associated with the …

[PDF][PDF] 放射治疗相关肿瘤血管生成的研究进展

黄皓, 周光明, 胡文涛 - 激光生物学报, 2020 - jgsw.hunnu.edu.cn
放射治疗是临床肿瘤治疗中一种广泛使用的物理疗法, 然而, 辐射引起的肿瘤转移往往会导致
治疗失败. 肿瘤转移和肿瘤血管生成密切相关, 抗血管生成药物联合放疗可显著改善临床肿瘤 …

Establishment of a 21-color Panel for the Detection of Immune Cell Subsets in Human Non-small Cell Lung Cancer Tumor Tissues with Flow Cytometry.

GUO Tingting, XIE Hongguan - Chinese Journal of Lung …, 2024 - search.ebscohost.com
Background and objective With the rise of multicolor flow cytometry, flow cytometry has
become an important means to detect the immune microenvironment of lung cancer, but …

Establishment of a 21-color Panel for the Detection of Immune Cell Subsets in Human Non-small Cell Lung Cancer Tumor Tissues with Flow Cytometry

T Guo, H Xie - Zhongguo fei ai za zhi= Chinese Journal of Lung …, 2024 - europepmc.org
Background With the rise of multicolor flow cytometry, flow cytometry has become an
important means to detect the immune microenvironment of lung cancer, but most of them …

The Feasibility of Using Emerging Antibody-drug Conjugates for the Treatment of Small Cell Lung Cancer

H Liu - MedScien, 2024 - deanfrancispress.com
Antibody-drug conjugate (ADC) consists of three parts: antibodies, linkers, and cytotoxic
payloads. With the deepening of research on ADC, the potential therapeutic effects of ADC …